CELL INTELLIGENCE · 肿瘤细胞治疗研究

p95HER2.CAR-TECH2Me（HER2CAR-T 细胞）治疗胃癌、乳腺癌：I 期临床试验

A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Im

这是一项 I 期注册临床试验，评估 HER2CAR-T 细胞治疗胃癌、乳腺癌、子宫内膜癌的安全性、可行性及初步疗效。当前状态：招募中。计划入组 15 例。试验地点：欧洲 · 巴塞罗那（共 2 个中心）。登记号：NCT07593820。

靶向 γ-分泌酶复合物调控高侵袭性恶性肿瘤中的致癌 NOTCH 信号：一项系统综述

Modulation of Oncogenic NOTCH Signaling in Highly Aggressive Malignancies by Targeting the γ-Secretase Complex: A Systematic Review.

抗 HER2×CCR4 双特异性抗体通过趋化阻断和清除肿瘤相关 Tregs，增强晚期 HER2 阳性肿瘤的抗肿瘤免疫，且不诱导全身毒性

Anti-HER2×CCR4 bispecific antibody enhances antitumor immunity in advanced HER2-positive tumors by chemotaxis blockade and depletion of tumor-associat

XL-11 在晚期 HER2+肿瘤中介导强效抗肿瘤免疫，同时避免减少全身 Tregs。XL-11 还与抗 PD-1 治疗协同作用，并表现出良好的稳定性和 PK，支持临床转化。这项工作推进了 HER2+肿瘤中靶向 Treg 的疗法，并克服了 mogamulizumab 的治疗局限性。

间充质干细胞来源外泌体对主要实体恶性肿瘤的治疗潜力：一项叙述性系统综述

Therapeutic potentials of mesenchymal stem cell-derived exosomes for major solid malignancies: A narrative systematic review.

癌症中抗体-药物偶联物的耐药机制

Mechanisms of resistance to antibody-drug conjugates in cancers.

用于预测三阴性乳腺癌患者免疫检查点抑制剂应答的联合生物标志物

Combined Biomarkers for Prediction of Immune Checkpoint Inhibitor Response in Patients With Triple-negative Breast Cancer.

IMAGiC 与 iTIL 联合作为生物标志物，可指导转移性 TNBC 免疫治疗的临床决策。

揭示 gasdermin B 在癌症和炎症性疾病中的作用：从分子机制到治疗策略

Unveiling the role of gasdermin B in cancer and inflammatory disease: from molecular mechanisms to therapeutic strategies.

mRNA 递送在肿瘤免疫治疗中的应用

Applications of mRNA Delivery in Cancer Immunotherapy.

人表皮生长因子受体 2 阳性晚期胃癌或食管胃腺癌：回顾过去以获得新见解

Human Epidermal Growth Factor Receptor 2 Positive Advanced Gastric or Esophagogastric Adenocarcinoma: Reflecting on the Past to Gain a New Insights.

多组学分析揭示 NET1 参与肿瘤免疫调节和恶性进展

Multiomics analysis reveals the involvement of NET1 in tumour immune regulation and malignant progression.